Rezolute reports FY2025 net loss $74.4M; sunRIZE topline Dec 2025, FDA streamlines tumor HI trial

Rezolute, Inc.

Net loss of $24.4M for Q4 FY2025, $74.4M full year; cash $167.9M as of June 30, 2025 (up from $127.1M).
Phase 3 sunRIZE (congenital HI) fully enrolled with 62 participants; topline results expected December 2025.
FDA aligned on streamlined Phase 3 upLIFT (tumor HI) with as few as 16 participants; topline H2 2026.
Appointed Dr. Sunil Karnawat as Chief Commercial Officer in August 2025 to lead launch strategy.
R&D expenses $61.5M (FY2025) vs $55.7M; G&A $18.4M vs $14.7M; increases driven by trial and headcount.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.